View article

Background:  Behcet's disease (BD) is a vasculitis progressing by attacks and remissions. Not all patients will respond even to the classical treatments. New treatments are emerging with the hope to overcome this failure.

Biologic agents:  Interferon‐α (IFN‐α), anti‐tumour necrosis factor‐α (TNF‐α), and tolerization have been used in BD.

IFN‐α is mainly used for ocular manifestations of BD. The result seems impressive, 92% of cases had good or excellent results. It was less impressive for mucocutaneous and joint manifestations. The dosage is 6–9 million IU/day for 4 weeks, then 4.5 million daily for 4 weeks, and then 3 million/day. The maintenance dose is 3 millions, three times/week, to continue for 8 weeks after complete remission.

Etanercept (anti‐TNF‐α) was effective in mucocutaneous lesions of BD at the dosage of 25 mg twice weekly for 3 months (double‐blind control study). Attacks relapsed after …